# Safety and Preliminary Efficacy of TISA-818 Injection in Patients With Acute Respiratory Distress Syndrome

> **NCT07319351** · PHASE2 · COMPLETED · sponsor: **EnliTISA (Shanghai) Pharmaceutical Co., Ltd.** · enrollment: 57 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome (ARDS)

## Interventions

- **DRUG:** TISA-818-Inj
- **DRUG:** TISA-818-Inj
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07319351
- **Lead sponsor:** EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-12
- **Primary completion:** 2025-03-25
- **Final completion:** 2025-09-15
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07319351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07319351, "Safety and Preliminary Efficacy of TISA-818 Injection in Patients With Acute Respiratory Distress Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07319351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*